Clinical breast cancerHumansFemalePaclitaxelBreast NeoplasmsCarboplatin
Dose Adjusted Neoadjuvant Paclitaxel, Carboplatin, Trastuzumab and Pertuzumab in Women With HER2 Positive Early Breast Cancer.
Carolyn Moloney-Lineen, Maggie O'Connor, Caroline O'Leary, Paryani Hadia, David Solaligue, Philip Bredin, Gargi Roy, Megan Greally, Bryan T Hennessy, Patrick Glyn Morris
Published: 202510.1016/j.clbc.2025.09.014
Abstract
PURPOSE: Nine cycles of preoperative carboplatin with paclitaxel and anti-HER2 therapy is highly effective in early stage breast cancer. National guidelines include treating with 6 cycles of therapy with reduced dose of carboplatin. This study aimed…
Preview only. Read the full abstract at the source